David Reed, MD
Retina Specialist · Plymouth, MANPI 1932330990
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,222 of the $1,832 with a category attached, or 66.7%. Regeneron accounts for 66.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,222 and has fallen 88.3% since, to $143 in 2025.
Across 19 payments — averaging $96.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1K
- Regeneron Healthcare Solutions, Inc.$334
- Tarsus Pharmaceuticals, Inc.$125
- AbbVie$64
- Sight Sciences, Inc.$28
- Alcon$24
- plus $36 from 2 others
What the payments were for
- Consulting fees$1,22267%
- Food & beverage$61033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $1,222 |
| Regeneron Healthcare Solutions, Inc. | 9 | $334 |
| Tarsus Pharmaceuticals, Inc. | 1 | $125 |
| AbbVie(2 entities) | 3 | $64 |
| Sight Sciences, Inc. | 2 | $28 |
| Alcon | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,832 in reported general payments places this provider in the 65th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 76 | $18,755 |
| ProlensaBromfenac Sodium | 40 | $13,698 |
| Difluprednate | 81 | $7,737 |
| Prednisolone Acetate | 196 | $6,080 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 78 | $1,344 |
| Timolol Maleate | 70 | $698 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 82 | $521 |
| Ketorolac Tromethamine | 15 | $202 |
| Brimonidine Tartrate | 27 | $167 |
| Dorzolamide Hcl | 17 | $166 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Plymouth
- Jeffrey HeierBoston$1.5M
- Alyse RichardDartmouth$37K
- Andre WitkinBoston$23K
- Chirag ShahBoston$14K
- Elite Bor-ShavitLancaster$11K
- Rebecca SoaresSpringfield$10K
- Brian BalliosBoston$3K
- Brad BakerWorcester$2K
- Ilya LeskovBoston$2K
- Bryan HongWorcester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.